KPV
What We've Seen in Practice, and What the Research Says
KPV is one of the smallest peptides we work with, and one of the most focused. It is three amino acids long, lysine then proline then valine, and it comes from the very end of a hormone your body makes on its own. That parent hormone, alpha-MSH, does several unrelated jobs. KPV carries forward only one of them: it calms inflammation. Everything else about the parent molecule was left behind, which is exactly what makes this fragment interesting.
Most of what is known about KPV was learned in the laboratory, in cells and in animals, where it has been studied hardest for inflammation in the gut. The picture there is consistent and, in one respect, unusual: KPV appears to steer itself toward inflamed tissue rather than acting everywhere at once. We will walk through that below, and we will be equally clear about the limit, which is that KPV has not yet been tested in a completed human trial.
There is one more thing to say up front, because it shapes how we talk about KPV today. We used it for years and thought highly of it. A regulatory change in late 2023 closed the supply we trusted, so it left our shelf. That is a story worth telling plainly, and it is the first thing below.
.svg)
What we've seen in practice
For several years, KPV was a peptide we reached for often, and it earned its place. Dr. Koniver used it most for gut inflammation, and after that for joint pain, and across that stretch he does not recall a single adverse reaction. "We had great success with it," is how he puts it. For a small, targeted anti-inflammatory, KPV did what we asked of it and did it cleanly.
It rarely worked alone in our hands, and that was by design. KPV was one of four peptides in an anti-inflammatory recovery approach we built around BPC-157, TB-500, GHK-copper, and KPV together. Each of the four is useful on its own. Combined, in Dr. Koniver's experience, they move faster than any one of them does by itself, and KPV and BPC-157 in particular seemed to complement each other, working on inflammation from slightly different angles. Patients who came in with pain and irritation were often started on that combination.
Then the regulatory ground shifted. In the fall of 2023, KPV was placed in the FDA's Category 2, which closed the compounding channel we relied on to source it well. We stopped using it at that point. It is worth being precise about why, because the reason was not clinical. We did not lose confidence in KPV. We lost access to a supply we trusted, and we are not willing to reach for research-chemical material of unknown quality to fill that gap. So KPV moved off our active list, and BPC-157's successor, PDA, took over much of the anti-inflammatory work it used to do.
Dr. Koniver has been candid that he misses it. "I wish it was still available. We really like KPV," he has said, adding that he hopes more peptides like it become available again. As of this year, that hope has something behind it. In July 2026, KPV was among a small group of peptides an FDA advisory committee recommended for the compounding pathway.
The research behind these observations, including where the science is strong and where it simply has not been done yet, follows below.
KPV at a glance
A tripeptide, three amino acids (lysine-proline-valine), taken from the tail end of the natural hormone alpha-MSH; it carries the parent hormone's anti-inflammatory activity and none of its other effects [1, 7]
.svg)
Inflammation, most heavily in the gut (inflammatory bowel disease), and also skin, wound healing, and joints, all in cells and animals [1, 2, 3, 6]
.svg)
Preclinical. Two decades of cell-culture and rodent studies plus a 2025 human-skin-cell study; no completed human trial yet [1, 3, 6]
.svg)
By injection, by mouth, or topically in the research literature, depending on the target
.svg)
Formula C16H30N4O4 · weight 342.43 g/mol · 3 amino acids (sequence Lys-Pro-Val) [7]
Not approved anywhere; FDA Category 2 in late 2023, prohibition lifted April 2026, recommended (not yet approved) for compounding by an FDA advisory committee July 2026; not currently on the WADA list
We used KPV for years, mainly for gut inflammation and joint pain, as part of an anti-inflammatory recovery combination; it left our shelf when the supply channel closed in 2023. See what we've seen in practice above
The whole peptide, three amino acids in order (Lys-Pro-Val). Its small size is the point: it is what lets KPV survive the gut and be actively transported into inflamed tissue.
Where KPV comes from
Your body makes a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. It is a short chain of thirteen amino acids, and it is a busy molecule: it influences skin pigment, appetite, and other signals that have nothing to do with one another. Tucked at the very end of that chain are its last three amino acids, lysine, proline, and valine. KPV is just that tail, synthesized on its own.
What researchers found is that this tail is where much of alpha-MSH's anti-inflammatory activity lives. Cut it loose from the rest of the hormone and you get a molecule that quiets inflammation without carrying pigmentation or appetite effects along with it. In several laboratory comparisons, the small fragment was actually the stronger anti-inflammatory of the two, and being smaller made it more stable and easier to work with than the full hormone. That is the whole idea behind KPV: keep the useful signal, drop everything else, and end up with something more focused than the molecule it came from.
How KPV works
.svg)
Chronic inflammation runs largely through two internal signaling systems, NF-kB and MAPK. In laboratory studies, KPV turns both of them down, lowering the output of inflammatory messengers. What is notable is what it does not do: it calms these pathways without broadly shutting off the immune system the way stronger immune-suppressing drugs can. [1, 2]
.svg)
KPV is small enough that some of an oral dose survives digestion, and it is carried into the cells lining the gut by a transporter called PepT1. Here is the useful part: PepT1 becomes more abundant in gut tissue that is already inflamed. So KPV tends to accumulate where inflammation is worst rather than spreading evenly, a kind of built-in targeting that is unusual for a peptide. [1,3]
.svg)
The same anti-inflammatory activity has been studied in skin cells and wound models. In those settings KPV lowered inflammatory signaling and, in wounds, helped tissue move past the inflammatory stage toward repair. A 2025 study extended this to human skin cells under pollution stress. These remain laboratory findings, and we present them as such. [6]
A deep, consistent preclinical record - strongest in the gut - and a human chapter still unwritten [1, 3]
What the research shows
Here is the whole picture, told plainly. KPV has a deep and consistent preclinical record, concentrated in the gut, and no completed human trials.
The anchor is a 2008 study by Dalmasso and colleagues, which worked out the transporter mechanism and showed that oral KPV reduced the severity of colitis in two separate mouse models. A second group reported anti-inflammatory benefit in mouse inflammatory bowel disease that same year, from a different starting point. In 2016, a follow-up found that KPV also reduced inflammation-associated tumor formation in the colon of mice, and, tellingly, that benefit vanished in animals lacking a working PepT1 transporter, which confirmed the mechanism is doing the work. Later studies packaged KPV into nanoparticles and delivered the same anti-inflammatory effect at a small fraction of the ordinary amount. The newest, from 2025, tested KPV on human skin cells stressed by air pollution and saw the expected calming of inflammatory signaling.[1,2,3,4,5,6]
Now the limit, stated as plainly as the promise. Every one of those findings comes from a cell or an animal. No completed human trial of KPV has been run, and the FDA has specifically noted the absence of human exposure data for it by any route. Its interactions with common medicines such as biologics and corticosteroids have not been formally studied, and its long-term safety in people has not been characterized. None of that erases the preclinical record, which is genuinely strong for an anti-inflammatory of this size. It does mean the honest description of KPV is "a peptide with a consistent laboratory story and a human chapter still unwritten," and anyone presenting it as a settled human therapy is ahead of the evidence.
Gut inflammation (IBD)
Mouse colitis models (Dalmasso 2008; Kannengiesser 2008)
Oral KPV reduced colitis severity across models; PepT1 transport into inflamed tissue
Animal only; no human trials [1, 2]
Colitis-associated cancer
Mouse model (Viennois 2016)
Reduced inflammation-associated tumor formation; effect required PepT1
Animal only; not a human anti-cancer finding [3]
Delivery technology
Nanoparticle studies (Laroui 2010; Xiao 2017)
Same anti-inflammatory effect at far lower doses
Animal only; technique studies [4,5]
Skin and wound
Cell and wound models, incl. human skin cells (Sung 2025)
Lowered inflammatory signaling; supported wound resolution
Cell/animal only; no human trials [6]
The evidence, area by area
Tiers on this page: Animal / cell research Clinical · observation (our practice)· No completed human trials. The green chip marks areas where our own clinical use informs the picture; it is experience, not trial data.
Across the preclinical work, KPV was tolerated well, by injection, by mouth, and topically, and published animal data has not shown a tumor-promoting or liver-toxicity signal. Part of the reason is its origin: KPV is a fragment of a hormone the body already makes, and it is small enough that the immune system does not tend to flag it as foreign. In our own years of clinical use, Dr. Koniver does not recall an adverse reaction to it. That is a meaningful observation, and it is not the same as a controlled safety trial, which has never been done.
The honest cautions follow from the same gap. There is no human safety data and no formal study of how KPV behaves in the body over time in people. Because it modulates the immune response, we would not combine it casually with biologics or other strong immune-modulating drugs whose interaction with it is unstudied. We would not use it during pregnancy or breastfeeding, or in someone with an active infection. And because the regulated supply has been closed, the material sold as KPV today generally comes from research-chemical suppliers of unknown purity, which is a real and separate hazard from the peptide itself.
Regulatory status
The following is descriptive, not advice. Regulatory status changes; the date below is when we last checked.
KPV has moved through three stages in the FDA's compounding review. The reference material we started from stops at the middle step; the third is the current one.
Placed in FDA 503A Category 2 (safety concerns; FDA stated it lacks human exposure data by any route). The compounding channel closed.
Nomination withdrawn and the Category 2 prohibition lifted. Removal is not the same as approval.
An FDA advisory committee recommended KPV among six peptides for the 503A pathway. Advisory only; the FDA has not yet acted.
As a medicine,
worldwide
Not an approved medicine in any country, and no approved therapeutic use.
In competitive sport
Not currently listed
KPV is not currently named on the WADA Prohibited List. WADA revises that list every January, so any competitor should confirm the current status before use.[9]
Everywhere else,
in general
No national health authority has approved KPV for medical use. Availability and rules vary by country, and status can change.
Regulatory information current as of 12 August 2026.
KPV, answered plainly
It is a tripeptide, three amino acids (lysine, proline, valine), taken from the end of a natural hormone called alpha-MSH. It carries that hormone's anti-inflammatory activity without its other effects, and it has been studied mainly for inflammation in the gut.
We cannot say that, because it has not been tested in a completed human trial.
FROM THE RESEARCH
In mice, oral KPV reduced colitis severity and traveled selectively into inflamed gut tissue. That is an encouraging animal result, not a human treatment claim, and we are careful about the difference. [1]
Not because it stopped working for us. When KPV was placed in FDA Category 2 in late 2023, the regulated channel we used to source it closed, and we do not substitute unverified research-chemical material. We moved much of that anti-inflammatory work to PDA.
In preclinical studies and in our own clinical experience it has been well tolerated, and Dr. Koniver does not recall an adverse reaction to it. But there is no human safety trial, no long-term human data, and no formal study of how it interacts with immune-modulating drugs. Unregulated product quality is a separate, real risk.
It is not currently listed by WADA, but that list is reviewed annually and can change. Any competitor should verify the current status before use. The regulatory section above has the detail. [9]
Related in this directory
References
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177. (Mouse colitis; foundational.)
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346.
- Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PMID 27458604.
- Xiao B, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. PMID 28143741.
- Laroui H, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-853. PMID 19909746.
- Sung J, et al. Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. Tissue Cell. 2025. PMID 40073467. (Human skin cells in vitro.)
- PubChem. L-Lysyl-L-prolyl-L-valine, alpha-MSH (11-13) free acid (CID 125672): C16H30N4O4, 342.43 g/mol.
- US FDA. 503A compounding review: KPV Category 2 (2023) → withdrawn/prohibition lifted 22 April 2026 → PCAC recommended 23-24 July 2026 (advisory).
- WADA. The Prohibited List (KPV not currently listed; reviewed annually).
This page is for informational and educational purposes and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for consultation with a qualified healthcare provider. KPV is not approved by the FDA or any national health authority for therapeutic use and has not been tested in completed human clinical trials. Statements describing how Dr. Koniver and the Koniver Wellness team have used and view KPV reflect clinical experience and judgment, which is not the same as controlled clinical evidence. Regulatory information on this page is provided for general awareness, is current as of the date shown, and may have changed; verify with official sources or a licensed practitioner in your jurisdiction before making any decision. Koniver Wellness serves a worldwide readership: the availability and regulatory status of the therapies discussed vary by country and region, so please check the laws and regulations of your own jurisdiction and consult a licensed local practitioner before pursuing any therapy. Availability of any given peptide depends on its regulatory and supply status. Therapies described on this site are prescribed and supervised by licensed physicians for Koniver Wellness patients. Use of this site does not create a physician-patient relationship.
INTERESTED IN PEPTIDES?
START WITH THE RIGHT QUESTIONS.
Understand what peptides can and cannot do, what the evidence actually says, and whether physician-guided peptide therapy makes sense for you.